Capricor Therapeutics Q2 Net Loss $40.7M; Deramiocel BLA Under FDA Review

Capricor Therapeutics reported a net loss of $40.7 million for the second quarter of 2026, an increase from $25.9 million in the same period last year, with total operating expenses rising to $42.9 million. The company maintained a strong cash position of $237.9 million as of June 30, 2026, sufficient to fund operations for at least the next twelve months. The Biologics License Application (BLA) for Deramiocel remains under active FDA review, despite a negative Advisory Committee vote (3 in favor, 9 against) regarding its use for cardiomyopathy in Duchenne Muscular Dystrophy, though feedback on upper limb function was supportive. The full HOPE-3 Phase 3 dataset, demonstrating statistically significant slowing of upper limb disease progression, was published in The Lancet.